Simply put - the share structure.
I believe it's in my sticky.
Neurotrope has had insider funding and is insider controlled through a few "wealth management" funds.
Just as high institutional ownership allows institutions and hedge funds like BlackRock to whipsaw a stock to shake out retail, high insider control has the ability to do the same.
Anavex has an active long term retail share base and institutions are having trouble shaking them out with volatility to get cheap positions. They have also offered stockholders an anti-takeover poison pill that retail actually participates in, it will be voted on at the next shareholder meeting.
Dollar per dollar, I believe that even if both drugs are successful my rights as a shareholder are safer when invested in Anavex and I have a greater chance of benefiting financially from the success of the company.
Beyond that, direct stimulation of synapse growth with a growth factor does not seem like a practical long term treatment. If I fertilize my plants too much they die. Maintenance of cellular homeostasis as in Anavex 2-73 seems like a more reasonable long term treatment goal. It is possible that the Neurotrope drug could be used to "jump start" severe cases but I do not see it as a widely used prophylactic drug which is likely for 2-73.
Market Data 
Markets 
AI
